This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Patients who transitioned to the oral daily formulation after a lengthy treatment with the weekly IV formulation improved further in this assessment of exercise tolerance, which is the primary endpoint of the ongoing Phase 3 LEVEL study. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,
Circulation, Ahead of Print. Use of separate rule-in and rule-out diagnostic thresholds stratified by BMI reduces miscategorization and can guide more appropriate use of exercise testing for possible HFpEF.
Circulation: Heart Failure, Volume 16, Issue 11 , Page e010633, November 1, 2023. BACKGROUND:Heart failure with preservedejectionfraction is associated with significant functional limitations, yet treatments for improving exercise performance have been elusive.
Circulation: Heart Failure, Ahead of Print. BACKGROUND:In heart failure, sympathetic excess and exercise intolerance impair quality of life. In heart failure with reduced ejectionfraction, exercise stimulates a reflex increase in muscle sympathetic nerve activity (MSNA) that relates inversely to peak oxygen uptake (VO2peak).
Circulation: Heart Failure, Volume 16, Issue 11 , Page e010618, November 1, 2023. BACKGROUND:Obesity and adiposity are associated with an increased risk of heart failure with preservedejectionfraction (HFpEF); yet, specific underlying mechanisms remain unclear. mL/kg per min lower peak VO2(β, −2.35±0.19;P<0.001).
Among patients with heart failure with preservedejectionfraction (HFpEF), right ventricular (RV) dysfunction is strongly associated with an increased risk of morbidity and mortality.
Circulation: Heart Failure, Volume 16, Issue 12 , Page e010673, December 1, 2023. mm Hg with exercise (P<0.001). mm Hg with exercise (P<0.001). At peak exercise, RT was responsible for 64% (53%–76%) of end-diastolic pressure, whereas incomplete relaxation and stiffness accounted for the rest.
Circulation, Ahead of Print. BACKGROUND:Metabolic distress is often associated with heart failure with preservedejectionfraction (HFpEF) and represents a therapeutic challenge. Metabolism-induced systemic inflammation links comorbidities with HFpEF.
Circulation, Volume 150, Issue Suppl_1 , Page A4134456-A4134456, November 12, 2024. Introduction:Heart failure with preservedejectionfraction (HFpEF) is a form of heart failure which is rapidly rising in incidence in the US today. Despite this, no therapies with mortality benefit exist for this syndrome.
Circulation, Volume 150, Issue Suppl_1 , Page A4139791-A4139791, November 12, 2024. Intro:Drug Development for Heart failure with PreservedEjectionFraction (HFpEF) is a major challenge facing cardiovascular research due to its complex pathophysiology and existence of comorbidities, leading to recognize distinct HFpEF phenogroups.
Circulation, Ahead of Print. BACKGROUND:Sodium-glucose cotransporter 2 inhibitors reduce the risk of worsening heart failure (HF) and cardiovascular death in patients with HF irrespective of left ventricular ejectionfraction. Dapagliflozin did not improve these outcomes in patients with HF with preservedejectionfraction.
Circulation, Volume 150, Issue Suppl_1 , Page A4118122-A4118122, November 12, 2024. The primary outcomes were exercise capacity, diastolic function, and quality of life at baseline evaluation. After controlling for potential confounding variables, there were no differences in baseline exercise capacity [peak VO2 (mL/kg/min): 12.1
Circulation, Ahead of Print. Background: Patients with heart failure, a preservedejectionfraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heart failure. The broad spectrum of effects was reflected in benefits on the hierarchical composite (win ratio 1.63, 95%CI, 1.17, 2.28;P=0.004).Conclusions:
Circulation, Ahead of Print. Background:Patients with heart failure (HF) with preservedejectionfraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. mg improved symptoms, physical limitations and exercise function, and reduced inflammation and body weight.
4] More recently, at least at the epidemiologic level, the obesity paradox has been confirmed in both heart failure with reduced ejectionfraction (HFrEF) and heart failure with preservedejectionfraction (HFpEF), but also in those with coronary heart disease. [5, Circulation Research 118.11 (2016): 1752-1770.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
105 
Let's personalize your content